Research Paper Volume 13, Issue 1 pp 437—449

Accumulation of LOX-1+ PMN-MDSCs in nasopharyngeal carcinoma survivors with chronic hepatitis B might permit immune tolerance to epstein–barr virus and relate to tumor recurrence

Accumulation of LOX-1+ PMN-MDSCs in NPC survivors. (A) Gating strategy and statistical analysis of LOX-1+ PMN-MDSCs by flow cytometry analysis in NPC survivors with CHB (NPC-CHB), NPC survivors with LC (NPC-LC), and their control, including NPC survivors without CHB, patients with CHB and patients with LC, and healthy donors (Con). (B) Typical morphology of sorted LOX-1+ PMN-MDSCs from each group and LOX-1−PMN. Abbreviations: PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; NPC, nasopharyngeal carcinoma; CHB, chronic hepatitis B; LC, liver cirrhosis.

Figure 1. Accumulation of LOX-1+ PMN-MDSCs in NPC survivors. (A) Gating strategy and statistical analysis of LOX-1+ PMN-MDSCs by flow cytometry analysis in NPC survivors with CHB (NPC-CHB), NPC survivors with LC (NPC-LC), and their control, including NPC survivors without CHB, patients with CHB and patients with LC, and healthy donors (Con). (B) Typical morphology of sorted LOX-1+ PMN-MDSCs from each group and LOX-1PMN. Abbreviations: PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; NPC, nasopharyngeal carcinoma; CHB, chronic hepatitis B; LC, liver cirrhosis.